What is the Semax/Selank Mix used for?

It is supplied strictly for in vitro laboratory research, not for human or veterinary use. Semax and Selank are approved medicines in Russia for specific indications, but neither holds an EU or US marketing authorisation, and the research-grade blend sold here is a research chemical only.

How does Semax's neurotrophin activity relate to its reported nootropic effects?

In Russian preclinical work, Semax has been reported to regulate BDNF and TrkB signalling (Dolotov et al., 2006), which is linked in animal models to synaptic plasticity, alongside nitric-oxide-related neuroprotective activity. Neurotrophin modulation is one proposed mechanism for its nootropic profile, not an established primary mode of action, and it has not been tested as part of a Semax/Selank combination.

Why does Selank, an anxiolytic peptide, also show immunomodulatory activity?

Selank is a synthetic analogue of tuftsin, an endogenous immunomodulatory peptide. In mice, Selank and its fragments changed expression of chemokine, cytokine and receptor genes in spleen, while separate preclinical studies reported antiviral activity. These findings do not establish a clinical immunologic effect, and they do not describe the Semax/Selank blend.

What side effects has Semax been associated with in published research?

Clinical use of Semax nasal drops in Russia has generally been described as well tolerated, with occasional reports of local nasal irritation. Controlled long-term human safety data outside its Russian clinical framework are limited, and none exist for the research-grade material sold internationally. It should be treated strictly as an unapproved research chemical, not a substance with an established human safety profile.

Are there known side effects associated with Selank in the research literature?

The small indexed Selank studies do not provide systematic adverse-event reporting, and the main human comparison was open label against medazepam rather than placebo. Its authors described a less sedative profile than the benzodiazepine comparator, but absence of reported events cannot establish a low adverse-effect rate or long-term safety. No safety data exist for combined Semax-plus-Selank administration or for the research-grade blend sold here.

How does the Semax/Selank combination compare to Noopept in research studies?

In Vasil'eva et al. (2020), Selank, Semax and Noopept were each tested SEPARATELY in BALB/c mice, where route-dependent nootropic and anxiolytic effects were reported; C57BL/6 mice largely did not show the same effects. Noopept is a different chemical class (a proline-derived compound, not a neuropeptide) and is not part of the mix. The study compares the individual compounds; it does not test the Semax/Selank combination.

Does the route of administration matter for how Semax and Selank act together?

The available route comparison (Vasil'eva et al., 2020) tested the peptides SEPARATELY, not as a mix, and the effects were strain-dependent (seen in BALB/c but largely not in C57BL/6 mice). It suggests route can influence each peptide's effect, but because no study has tested the two given together, it does not tell us how a Semax/Selank mix behaves by any route.

Are there human studies on the Semax/Selank combination?

No. The main human imaging study (Panikratova et al., 2020, Doklady Biological Sciences, PMID 32342318) gave Semax, Selank or placebo as SEPARATE administrations and reported distinct connectivity effects for each. No published human study has tested combined Semax-plus-Selank administration, so there is no direct human evidence about the mix itself.

What doses were used in Semax and Selank research?

Published rat studies reported intranasal Semax doses of 50 or 250 µg/kg for specific BDNF and ischemia endpoints, while mouse and rat Selank studies reported 300 µg/kg intranasally; some route-comparison work also used intraperitoneal administration. Russian labeling lists Semax 0.1% and 1% and Selank 0.15% nasal drops. The indexed Selank human abstract does not report an absolute dose. These are reported study or labeling figures, not recommendations. No controlled human dosing protocol exists for the combination.

Is it legal to purchase the Semax/Selank Mix in the EU?

Semax and Selank are approved medicines in Russia, but neither holds an EU marketing authorisation. Their status elsewhere must be checked jurisdiction by jurisdiction. There is no single EU-wide category for research peptides, so legality depends on presentation, intended use and each member state's national law. We sell strictly for laboratory research and not for human consumption; researchers should confirm the import and research-chemical rules in their own country, and this is not legal advice.

How can I verify the certificate of analysis for a Semax/Selank Mix batch?

The current blend carries a manufacturer-supplied Janoshik report showing per-component identity and content for Semax and Selank; PeptidesDirect did not commission or independently retest it. Match the batch or lot number on the vial to the number on the certificate, and where the lab offers a verification link or code, cross-check the report against the lab's own records. The current certificate is listed at /coa.

What does a per-peptide analysis actually mean for a two-component mix?

For a blend, it is more informative to see identity and content reported for Semax and Selank individually than a single combined vial figure, because one weak component can be hidden in an average. The current manufacturer-supplied report shows per-component identity and content rather than a guaranteed fixed purity percentage, so read the actual reported values on the batch certificate rather than assuming a specific number.

When would a researcher choose the premix over sourcing Semax and Selank separately?

The premix suits protocols that want the labeled 1:1 composition and want to reduce a manual weighing and mixing step. A protocol that needs a different Semax-to-Selank ratio, or that studies one peptide in isolation, would still use individually sourced vials. The choice depends on the research design rather than one option being universally better; a premix reduces manual steps but does not by itself eliminate all mixing or manufacturing variation.

What is needed to reconstitute the Semax/Selank Mix for laboratory use?

Add a validated solvent slowly down the vial wall and mix by gentle swirling rather than vigorous shaking. A syringe is used only as a laboratory measuring tool to add solvent accurately and withdraw aliquots for research, not for injection into a person or animal. Follow the specific product's documentation for the solvent and concentration rather than a single universal recipe.

Why is it important to avoid freeze-thaw cycles after reconstituting the mix?

Repeated freezing and thawing of a reconstituted peptide solution can promote degradation and aggregation, reducing the effective concentration of both Semax and Selank over successive cycles. Preparing single-use aliquots before freezing, or keeping the solution refrigerated for short-term use, avoids this repeated stress and helps preserve the peptides for the research protocol.

What should I check before buying a research peptide like the Semax/Selank Mix online?

Look for a batch-specific certificate of analysis rather than a generic one, per-component identity and content for each peptide in a blend, and a named testing laboratory with the source disclosed (manufacturer-supplied, community-submitted or independently commissioned). It is also worth checking that the labeled composition is stated and that reported values are matched to the specific lot on the vial.

Buy Semax/Selank Mix: Combined Nootropics for Neuroscience Research

The two peptides originated from research at the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax has been studied for cognitive, neurotrophin- and neuroprotection-related endpoints, while Selank has been studied for anxiety-related, GABA-system, monoamine and immune endpoints. These separate lines of research do not establish complementary activity or any effect of combined administration.

Semax/Selankcognitive

Pre-mixed combination of the two leading nootropic peptides in one vial. Semax boosts focus and BDNF, Selank reduces anxiety and enhances calm. Together they provide balanced cognitive enhancement for research.

The Semax/Selank Mix places these two peptides in one research reagent. Published cognitive-, anxiety- and connectivity-related studies administered Semax or Selank separately; whether the blend affects any such endpoint, or whether the peptides interact or act additively or synergistically, has not been established.

What Is the Semax/Selank Mix?

The mix contains 20 mg (10 mg Semax + 10 mg Selank) in one vial:

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic ACTH(4-10) analogue. In Russian preclinical work it has been reported to modulate neurotrophins, including BDNF and TrkB signalling (Dolotov et al., 2006), with effects on NGF described in later Russian preclinical studies, and to show neuroprotective and cognitive effects in animal models. Neurotrophin modulation is one proposed mechanism, not an established primary mode of action.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic tuftsin analogue studied for anxiety-related, GABA-system, monoamine and immune endpoints. The relevant evidence includes rat and mouse gene-expression, neurochemical and behavioral studies plus preclinical antiviral models; it does not establish clinical effects or any effect of the blend.

Both peptides contain a C-terminal Pro-Gly-Pro motif associated with increased resistance to proteolytic degradation in this peptide family; it does not ensure complete enzymatic stability. This is a common design principle originating from the same research group.

Why the Combination?

Research Rationale

The rationale for the Semax/Selank Mix is based on the recognition that cognitive performance and emotional regulation are inseparably linked. Anxiety and stress impair cognitive function, and conversely, cognitive overload can amplify anxiety. The research rationale is to examine cognitive and anxiety-related endpoints in the same experimental system. This does not establish that the blend affects either endpoint or that its effects are complementary, additive or synergistic:

Semax - cognitive axis:

Reported to regulate BDNF and TrkB in Russian preclinical work (Dolotov et al., 2006)
Has neurotrophin- and neurogenesis-related findings in specific rodent models; these do not establish a general effect in humans
Improves learning and memory performance in animal models
In a rat incomplete-global-ischemia model, Semax prevented excess cortical NO production and neurological disturbances; this association does not establish NO modulation as the causal pathway

Selank - emotional axis:

Affected expression of genes involved in GABAergic neurotransmission in rats; the authors described allosteric modulation as a possible mechanism (Volkova et al., 2016, PMID 26924987)
Reported anxiety-related behavioral effects in selected animal models; these data do not establish an absence of sedation in humans or for the blend
Produced strain- and region-dependent changes in monoamine levels and metabolites in mice; these data do not establish mood stabilization
Changed immune-gene expression in mouse spleen and showed antiviral activity in preclinical influenza models; these findings do not establish clinical effects or effects of the blend

Scientific Evidence

Panikratova et al. (2020, Doklady Biological Sciences, PMID 32342318): This study examined resting-state functional connectivity in healthy subjects who received Semax, Selank or placebo as SEPARATE administrations, not as a combination. It reported distinct connectivity effects for each peptide on predefined regions of interest including the amygdala. It does not test the two peptides given together, so it is not evidence about the mix.

Vasil'eva et al. (2020, Neurochemical Journal): This Russian preclinical study compared Selank, Semax and Noopept given SEPARATELY by different routes. In BALB/c mice, route-dependent nootropic and anxiolytic effects were reported; C57BL/6 mice largely did not show the same effects, and one comparison reported an opposing Semax anxiety result. The strain and route dependence, and the fact that the peptides were tested separately, mean this does not establish how a Semax/Selank mix behaves.

Mechanistic Findings Reported Separately

No published study has tested the Semax/Selank combination itself. The pathways below are reported SEPARATELY for each peptide, mostly in Russian preclinical work; their combined activity has not been tested, so this is a map of the individual mechanisms, not a demonstrated five-system combination effect:

Neurotrophin-related findings (Semax): Rat studies report time- and region-dependent changes in BDNF, NGF and related receptors. Dolotov et al. (2006) supports BDNF/TrkB-related effects, while later preclinical work addresses NGF. Neurotrophin modulation is one proposed mechanism, not an established primary mode of action.
GABAergic findings (Selank): Rat gene-expression and in-vitro binding studies support GABA-system modulation as a proposed mechanism. They do not establish enhanced inhibitory neurotransmission, absence of sedation or the behavior of the blend.
Monoaminergic System (both): Semax influences dopaminergic pathways, Selank modulates serotonin and noradrenaline metabolism. No study has shown broader monoaminergic modulation from combined administration.
NO-related findings (Semax): In a Wistar-rat incomplete-global-ischemia model, Semax prevented excess cortical NO production and neurological disturbances. This association does not establish NO modulation as the causal neuroprotective mechanism or a general effect in oxidative stress.
Immune-related findings (Selank): In mice, Selank and its fragments changed expression of chemokine, cytokine and receptor genes in spleen; separate preclinical studies reported antiviral activity. These findings do not establish phagocyte activation by Selank, clinical immunomodulation or an effect of the blend.

Quality Criteria When Purchasing

For a mix of two peptides, particularly stringent requirements apply:

Per-component identity and content: A useful certificate reports identity and content for Semax and Selank individually, not just a combined vial weight.
Which lab, and what was tested: The current Semax/Selank Mix batch carries a manufacturer-supplied Janoshik report showing per-component identity and content; PeptidesDirect did not commission or independently retest it. The certificate is listed on our lab-reports page at /coa.
Labeled composition: The product is labeled as a 1:1 (10 mg + 10 mg) composition; check the reported content against that label rather than assuming an exact ratio.

Dose Figures in the Research Literature

No dosing study exists for the mix itself, and no combined Semax-plus-Selank protocol has been published. The figures below are reported for the individual peptides and are references from the literature, not a dosage recommendation:

Semax: In rats, published studies used single intranasal doses of 50 or 250 µg/kg for BDNF-related endpoints, while another study used 250 µg/kg/day intranasally for 6 days in a focal-ischemia model. Russian labeling lists 0.1% and 1% nasal drops. These are reported study or labeling figures, not recommendations.
Selank: Mouse and rat studies reported 300 µg/kg intranasally, with some route-comparison work also using intraperitoneal administration. The indexed abstract of the small Russian human comparison does not state the absolute dose. Russian labeling lists 0.15% nasal drops. These are reported study or labeling figures, not recommendations.

These are per-peptide figures reported in the literature or in Russian product labeling. No controlled human dosing protocol exists for the combination, and these figures do not convert into one.

Storage

The Semax/Selank Mix is supplied as lyophilized powder:

Before reconstitution: Follow the supplier's documented storage for the unopened lyophilized material, kept cold and protected from light and moisture.
After reconstitution: There is no single validated post-reconstitution shelf life for this blend; treat a reconstituted vial as a short-lived working solution, keep it cold, and rely on the specific product's stability data rather than a fixed number of weeks.
Reconstitution: Add a validated solvent slowly down the vial wall and mix by gentle swirling rather than vigorous shaking.
Freeze-thaw: Repeated freezing and thawing can degrade many peptides; where frozen storage is used, single-use aliquots are preferable to refreezing a whole vial.

Why Buy the Semax/Selank Mix from PeptidesDirect?

Documented certificate: A manufacturer-supplied Janoshik report with per-component identity and content, listed at /coa.
Pre-mixed: A labeled 1:1 (10 mg + 10 mg) composition in one vial, which reduces manual weighing and mixing steps.
EU shipping: Shipped from within the EU customs territory with tracked delivery; see the shipping page for current destination-specific estimates.
Value: Buying the blend can be more economical than sourcing the two peptides separately; the current price is shown on the product page.

Frequently Asked Questions